Applied Clinical Trials
Industry news focusing on the people and organizations who work in the clinical trials profession.
Melynda Geurts
• Melynda Geurts, chief operating officer of D.L. Anderson (Dallas, TX), and Roy Fleischmann, MD, medical director of Metroplex Clinical Research Center (Dallas, TX), have both been elected as the newest members of D.L. Anderson's Board of Directors.
Roy Fleischmann
• After serving as head of preclinical development for Medigene AG (Munich, Germany) for the last nine years, Ulrich Moebius will now take on the position of head of preclinical development and project management at MorphoSys (Munich, Germany).
Ulrich Moebius
• The role of business development executive at Penn Pharma's (Wilmington, DE) North American location will be filled by James Knapp, who joins the company after a seven-year tenure at Almac (Craigavon, UK).
James Knapp
• Formerly holding senior positions in professional services and implementation management, William Broucek will now serve in the newly developed position of senior director, professional services, at Velos (Fremont, CA).
• With more than 20 years experience in virology drug development, Sharon Lynn Benoit will now serve as INC Research's (Raleigh, NC) principal strategist of Infectious Disease.
• Applied Clinical Trial's Editorial Advisory Board member and executive director of the Good Clinical Practice Alliance, Europe, Francis P. Crawley, has been selected as the chairman of ICR's (Bourne End, UK) annual spring conference and exhibition working party.
• Of the 12 nominees for this year's European Inventor of the Year award, four come from the pharmaceutical arena: Jurg Zimmermann of Switzerland, Brian Druker of the United States, Yiqing Zhou and his team from China, and Germany's Maria-Regina Kula.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.